Article
Neurologic outcomes in people with multiple sclerosis treated with immune checkpoint inhibitors for oncologic indications
2024-06-13
Abstract excerpt
<h4>Objective</h4> To assess the prevalence of multiple sclerosis (MS) activity, as well as neurologic and non-neurologic immune-related adverse events (irAEs) in persons with MS (pwMS) treated with immune checkpoint inhibitors (ICIs) for cancer. <h4>Background</h4> ICIs are associated with irAEs and exacerbation of certain preexisting autoimmune diseases. PwMS are generally excluded from ICI clinical trials, so d...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 3b173029-a3fa-5b6b-be62-774293d0b0bb
- DOI
- 10.1101/2024.06.13.24308608
